Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lisinopril under fed conditions · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Lisinopril 40 mg Tablet under fed conditions. |
| 2 | ACTIVE_COMPARATOR | Lisinopril 40 mg Tablet (Zestril) |
| 3 | EXPERIMENTAL | Lisinopril 40 mg Tablet under fasting conditions. |
| Name | Type | Description |
|---|---|---|
| Lisinopril 40 mg Tablet (Zestril) under fed conditions. | DRUG | - |
| Lisinopril 40 mg Tablet under fasting conditions. | DRUG | - |
| Lisinopril 40 mg Tablet under fed conditions. | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Top 9 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |
Lisinopril under fed conditions refers to a 40 mg lisinopril tablet (Zestril) administered after food, studied to assess how a meal affects the drug's absorption. Lisinopril is an ACE inhibitor used to treat hypertension. The fed-state designation describes the dosing condition used in a bioequivalence study, not a separate medicine.
Lisinopril targets angiotensin-converting enzyme, or ACE, and acts as an ACE inhibitor. By inhibiting ACE, lisinopril reduces the conversion of angiotensin I to angiotensin II, which lowers blood pressure. This mechanism underlies its use in hypertension.
Novartis AG, which trades under the ticker NVS, is the developer associated with this lisinopril 40 mg tablet (Zestril) formulation studied under fed conditions. Lisinopril itself is a widely available generic ACE inhibitor, and this listing refers to the Novartis-associated product evaluated in the referenced trial.
Lisinopril under fed conditions was evaluated in a Phase 1 trial. The study is completed, and no active trials are ongoing for this specific fed-condition assessment. Lisinopril is an established hypertension therapy, and this Phase 1 work addressed bioequivalence rather than initial safety or efficacy testing.
Lisinopril under fed conditions was studied in NCT00883506, titled to demonstrate the relative bioequivalence of lisinopril 1 x 40 mg tablet under fasting and fed conditions. The Phase 1 trial enrolled 24 healthy male volunteers aged 18 years and older, was randomized and active controlled, and is completed.
Yes, lisinopril under fed conditions refers to the lisinopril 40 mg tablet also known as Zestril, given after food. Zestril is a brand name for lisinopril, an ACE inhibitor used for hypertension. The fed-condition wording describes how the tablet was administered in the bioequivalence study, not a different drug.